{"id":866692,"date":"2025-07-07T04:07:12","date_gmt":"2025-07-07T08:07:12","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt-2\/"},"modified":"2025-07-07T04:07:12","modified_gmt":"2025-07-07T08:07:12","slug":"investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt-2\/","title":{"rendered":"INVESTOR ALERT: Wolf Haldenstein Announces Class Action Lawsuit Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT)"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">NEW YORK<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">July 7, 2025<\/span><\/span> \/PRNewswire\/ &#8212; <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4461682-1&amp;h=31847836&amp;u=https%3A%2F%2Fwww.whafh.com%2Fcase%2Fsarepta-therapeutics-inc-nasdaq-srpt%2F&amp;a=Wolf%C2%A0Haldenstein+Adler+Freeman+%26+Herz+LLP\" target=\"_blank\" rel=\"nofollow\">Wolf\u00a0Haldenstein Adler Freeman &amp; Herz LLP<\/a> announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of <span class=\"xn-location\">New York<\/span> on behalf of investors who purchased or otherwise acquired <b>Sarepta Therapeutics, Inc.<\/b> (&#8220;Sarepta&#8221; or the &#8220;Company&#8221;) (NASDAQ: SRPT) securities between <b><span class=\"xn-chron\">June 22, 2023<\/span> and <span class=\"xn-chron\">June 24, 2025<\/span><\/b>, inclusive (the &#8220;Class Period&#8221;).<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/1064977\/Wolf_Haldenstein_Adler_Freeman_Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/1064977\/Wolf_Haldenstein_Adler_Freeman_Logo.jpg\" title=\"(PRNewsfoto\/Wolf Haldenstein Adler Freeman )\" alt=\"(PRNewsfoto\/Wolf Haldenstein Adler Freeman )\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>\n        <b>Investors who purchased or otherwise acquired shares of Sarepta should contact the <\/b><br \/>\n        <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4461682-1&amp;h=3980284024&amp;u=https%3A%2F%2Fwww.whafh.com%2Fcase%2Fsarepta-therapeutics-inc-nasdaq-srpt%2F&amp;a=Firm\" target=\"_blank\" rel=\"nofollow\"><br \/>\n          <b>Firm<\/b><br \/>\n        <\/a><br \/>\n        <b>\u00a0prior to the <span class=\"xn-chron\">August 25, 2025<\/span> lead plaintiff motion deadline.<\/b>\n      <\/p>\n<p class=\"prntac\">\n        <b><br \/>\n          <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4461682-1&amp;h=2061466256&amp;u=https%3A%2F%2Fwww.whafh.com%2Fcase%2Fsarepta-therapeutics-inc-nasdaq-srpt%2F&amp;a=PLEASE+CLICK+HERE+TO+JOIN+THE+CASE+AND+SUBMIT+CONTACT+INFORMATION\" target=\"_blank\" rel=\"nofollow\">PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION<\/a><br \/>\n        <\/b>\n      <\/p>\n<p>\n        <b>Allegations in the Complaint<\/b>\n      <\/p>\n<p>Sarepta is a biopharmaceutical company focused on genetic medicine, including its gene therapy product <b>ELEVIDYS<\/b>, developed for the treatment of Duchenne muscular dystrophy. According to the filed complaint, during the Class Period, Defendants made false and misleading statements concerning the safety profile, clinical development, and commercial prospects of ELEVIDYS.<\/p>\n<p>It is <span>alleged<\/span> that Sarepta:<\/p>\n<ul type=\"disc\">\n<li>Misrepresented the safety of ELEVIDYS, despite serious risks;<\/li>\n<li>Failed to detect or disclose severe adverse events during clinical trials;<\/li>\n<li>Withheld material information that eventually led to halted dosing, increased regulatory scrutiny, and suspension of shipments;<\/li>\n<li>Lacked a reasonable basis for positive statements about ELEVIDYS&#8217;s safety and potential for expanded use.<\/li>\n<\/ul>\n<p>\n        <b>Key Events and Stock Impact<\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>\n          <b><br \/>\n            <span class=\"xn-chron\">March 18, 2025<\/span><br \/>\n          <\/b>: <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4461682-1&amp;h=1274553543&amp;u=https%3A%2F%2Fwww.cgtlive.com%2Fview%2Fpatient-dies-acute-liver-failure-treatment-sarepta-dmd-gene-therapy-elevidys&amp;a=Sarepta+disclosed+the+death+of+a+patient+treated+with+ELEVIDYS.\" target=\"_blank\" rel=\"nofollow\">Sarepta disclosed the death of a patient treated with ELEVIDYS.<\/a>\u00a0Shares dropped <b>27.44%<\/b>, closing at <b><span class=\"xn-money\">$73.54<\/span><\/b>.<\/li>\n<li>\n          <b><br \/>\n            <span class=\"xn-chron\">April 4, 2025<\/span><br \/>\n          <\/b>: Sarepta halted certain clinical studies after European regulators called for a safety review. Shares fell <b>7.13%<\/b>, closing at <b><span class=\"xn-money\">$54.43<\/span><\/b>.<\/li>\n<li>\n          <b><br \/>\n            <span class=\"xn-chron\">June 15, 2025<\/span><br \/>\n          <\/b>: <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4461682-1&amp;h=3530416846&amp;u=https%3A%2F%2Fwww.biopharmadive.com%2Fnews%2Fsarepta-elevidys-duchenne-gene-therapy-death-second%2F750752%2F&amp;a=A+second+patient+death+due+to+acute+liver+failure+was+announced\" target=\"_blank\" rel=\"nofollow\">A second patient death due to acute liver failure was announced<\/a>, along with shipment suspensions. Shares plummeted <b>42.12%<\/b>, closing at <b><span class=\"xn-money\">$20.91<\/span><\/b>.<\/li>\n<li>\n          <b><br \/>\n            <span class=\"xn-chron\">June 24, 2025<\/span><br \/>\n          <\/b>: <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4461682-1&amp;h=2641664404&amp;u=https%3A%2F%2Fwww.cgtlive.com%2Fview%2Ffda-announces-investigation-deaths-following-treatment-sarepta-dmd-gene-therapy-elevidys&amp;a=The+FDA+issued+a+safety+communication+regarding+the+deaths\" target=\"_blank\" rel=\"nofollow\">The FDA issued a safety communication regarding the deaths<\/a>. Shares declined another <b>8.01%<\/b>, closing at <b><span class=\"xn-money\">$17.46<\/span><\/b> on <span class=\"xn-chron\">June 25, 2025<\/span>.<\/li>\n<\/ul>\n<p>\n        <b>Investor Action Deadline<\/b>\n      <\/p>\n<p>If you purchased Sarepta securities during the Class Period and suffered losses, you have until <b><span class=\"xn-chron\">August 25, 2025<\/span><\/b>, to request the Court appoint you as lead plaintiff.<\/p>\n<p>\n        <b>Why\u00a0<\/b><br \/>\n        <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4461682-1&amp;h=3162054530&amp;u=https%3A%2F%2Fwww.whafh.com%2Fcase%2Fsarepta-therapeutics-inc-nasdaq-srpt%2F&amp;a=Wolf+Haldenstein+Adler+Freeman+%26+Herz+LLP\" target=\"_blank\" rel=\"nofollow\"><br \/>\n          <b><br \/>\n            <span class=\"xn-person\">Wolf Haldenstein Adler Freeman<\/span> &amp; Herz LLP<\/b><br \/>\n        <\/a><br \/>\n        <b>?<\/b><br \/>\n        <b>:<\/b>\n      <\/p>\n<p>This illustrious<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4461682-1&amp;h=983030101&amp;u=https%3A%2F%2Fwww.whafh.com%2Fcase%2Fsarepta-therapeutics-inc-nasdaq-srpt%2F&amp;a=%C2%A0firm%2C\" target=\"_blank\" rel=\"nofollow\">\u00a0firm,<\/a>\u00a0founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements.\u00a0The <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4461682-1&amp;h=2553847027&amp;u=https%3A%2F%2Fwww.whafh.com%2Fcase%2Fsarepta-therapeutics-inc-nasdaq-srpt%2F&amp;a=law+firm%C2%A0\" target=\"_blank\" rel=\"nofollow\">law firm\u00a0<\/a>brings to the fore over 125 years of legal expertise in securities litigation and has a proven track record of protecting the rights of investors.<\/p>\n<p>We encourage all investors who have been suffered losses or have information that will assist in our investigation, to contact\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4461682-1&amp;h=211817004&amp;u=https%3A%2F%2Fwww.whafh.com%2Fcase%2Fsarepta-therapeutics-inc-nasdaq-srpt%2F&amp;a=Wolf+Haldenstein+Adler+Freeman+%26+Herz+LLP.\" target=\"_blank\" rel=\"nofollow\"><span class=\"xn-person\">Wolf Haldenstein Adler Freeman<\/span> &amp; Herz LLP.<\/a><\/p>\n<p>\n        <b>Contact:<\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>\n          <b>Phone:<\/b>\u00a0(800) 575-0735 or (212) 545-4774<\/li>\n<li>\n          <b>Email:\u00a0<\/b><br \/>\n          <a href=\"mailto:classmember@whafh.com\" target=\"_blank\" rel=\"nofollow\">classmember@whafh.com<\/a>\n        <\/li>\n<li>\n          <b>Contact Person:<\/b>\u00a0<a href=\"mailto:gstone@whafh.com\" target=\"_blank\" rel=\"nofollow\"><span class=\"xn-person\">Gregory Stone<\/span>, Director of Case and Financial Analysis<\/a><\/li>\n<\/ul>\n<p>\n        <b>Firm Website:<\/b>\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4461682-1&amp;h=3162054530&amp;u=https%3A%2F%2Fwww.whafh.com%2Fcase%2Fsarepta-therapeutics-inc-nasdaq-srpt%2F&amp;a=Wolf+Haldenstein+Adler+Freeman+%26+Herz+LLP\" target=\"_blank\" rel=\"nofollow\"><span class=\"xn-person\">Wolf Haldenstein Adler Freeman<\/span> &amp; Herz LLP<\/a><\/p>\n<p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY23368&amp;sd=2025-07-07\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt-302497262.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt-302497262.html<\/a><\/p>\n<p>SOURCE  <span class=\"xn-person\">Wolf Haldenstein Adler Freeman<\/span> &amp; Herz LLP<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NY23368&amp;Transmission_Id=202507070404PR_NEWS_USPR_____NY23368&amp;DateId=20250707\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire NEW YORK , July 7, 2025 \/PRNewswire\/ &#8212; Wolf\u00a0Haldenstein Adler Freeman &amp; Herz LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of investors who purchased or otherwise acquired Sarepta Therapeutics, Inc. (&#8220;Sarepta&#8221; or the &#8220;Company&#8221;) (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025, inclusive (the &#8220;Class Period&#8221;). Investors who purchased or otherwise acquired shares of Sarepta should contact the Firm \u00a0prior to the August 25, 2025 lead plaintiff motion deadline. PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION Allegations in the Complaint Sarepta is a biopharmaceutical company focused on genetic medicine, including its gene therapy product &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;INVESTOR ALERT: Wolf Haldenstein Announces Class Action Lawsuit Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-866692","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>INVESTOR ALERT: Wolf Haldenstein Announces Class Action Lawsuit Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"INVESTOR ALERT: Wolf Haldenstein Announces Class Action Lawsuit Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK , July 7, 2025 \/PRNewswire\/ &#8212; Wolf\u00a0Haldenstein Adler Freeman &amp; Herz LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of investors who purchased or otherwise acquired Sarepta Therapeutics, Inc. (&#8220;Sarepta&#8221; or the &#8220;Company&#8221;) (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025, inclusive (the &#8220;Class Period&#8221;). Investors who purchased or otherwise acquired shares of Sarepta should contact the Firm \u00a0prior to the August 25, 2025 lead plaintiff motion deadline. PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION Allegations in the Complaint Sarepta is a biopharmaceutical company focused on genetic medicine, including its gene therapy product &hellip; Continue reading &quot;INVESTOR ALERT: Wolf Haldenstein Announces Class Action Lawsuit Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-07T08:07:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1064977\/Wolf_Haldenstein_Adler_Freeman_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"INVESTOR ALERT: Wolf Haldenstein Announces Class Action Lawsuit Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT)\",\"datePublished\":\"2025-07-07T08:07:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt-2\\\/\"},\"wordCount\":473,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1064977\\\/Wolf_Haldenstein_Adler_Freeman_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt-2\\\/\",\"name\":\"INVESTOR ALERT: Wolf Haldenstein Announces Class Action Lawsuit Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1064977\\\/Wolf_Haldenstein_Adler_Freeman_Logo.jpg\",\"datePublished\":\"2025-07-07T08:07:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1064977\\\/Wolf_Haldenstein_Adler_Freeman_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1064977\\\/Wolf_Haldenstein_Adler_Freeman_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"INVESTOR ALERT: Wolf Haldenstein Announces Class Action Lawsuit Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"INVESTOR ALERT: Wolf Haldenstein Announces Class Action Lawsuit Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt-2\/","og_locale":"en_US","og_type":"article","og_title":"INVESTOR ALERT: Wolf Haldenstein Announces Class Action Lawsuit Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) - Market Newsdesk","og_description":"PR Newswire NEW YORK , July 7, 2025 \/PRNewswire\/ &#8212; Wolf\u00a0Haldenstein Adler Freeman &amp; Herz LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of investors who purchased or otherwise acquired Sarepta Therapeutics, Inc. (&#8220;Sarepta&#8221; or the &#8220;Company&#8221;) (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025, inclusive (the &#8220;Class Period&#8221;). Investors who purchased or otherwise acquired shares of Sarepta should contact the Firm \u00a0prior to the August 25, 2025 lead plaintiff motion deadline. PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION Allegations in the Complaint Sarepta is a biopharmaceutical company focused on genetic medicine, including its gene therapy product &hellip; Continue reading \"INVESTOR ALERT: Wolf Haldenstein Announces Class Action Lawsuit Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt-2\/","og_site_name":"Market Newsdesk","article_published_time":"2025-07-07T08:07:12+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1064977\/Wolf_Haldenstein_Adler_Freeman_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"INVESTOR ALERT: Wolf Haldenstein Announces Class Action Lawsuit Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT)","datePublished":"2025-07-07T08:07:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt-2\/"},"wordCount":473,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt-2\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1064977\/Wolf_Haldenstein_Adler_Freeman_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt-2\/","name":"INVESTOR ALERT: Wolf Haldenstein Announces Class Action Lawsuit Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt-2\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1064977\/Wolf_Haldenstein_Adler_Freeman_Logo.jpg","datePublished":"2025-07-07T08:07:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt-2\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1064977\/Wolf_Haldenstein_Adler_Freeman_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1064977\/Wolf_Haldenstein_Adler_Freeman_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-wolf-haldenstein-announces-class-action-lawsuit-against-sarepta-therapeutics-inc-nasdaq-srpt-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"INVESTOR ALERT: Wolf Haldenstein Announces Class Action Lawsuit Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/866692","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=866692"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/866692\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=866692"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=866692"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=866692"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}